# Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

> **NCT04705597** · PHASE2 · TERMINATED · sponsor: **BioAge Labs, Inc.** · enrollment: 194 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** BGE-175
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04705597
- **Lead sponsor:** BioAge Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-18
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-05-19
- **Target enrollment:** 194 (ACTUAL)
- **Why stopped:** The incidence of COVID-19 hospitalization cases decreased to a level that continued enrollment was no longer feasible
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705597, "Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04705597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*